Research Insight
Teva announced new data from the Phase III placebo-controlled and randomized First Time Use of SD-809 in HuntingtonDisease
Teva Pharmaceutical Industries Ltd., announced new data from the Phase III placebo-controlled and randomized First Time Use of SD-809 in HuntingtonDisease (First-HD) study evaluating...
Industry Reports
Teva to Report First Quarter 2016 Financial Results on May 9, 2016
Teva Pharmaceutical Industries Ltd. announced that it will release its first quarter 2016 financial results on Monday, May 9, 2016 at 7:00 a.m. ET....
Press Releases
Merck Receives Breakthrough Therapy Designation from U.S. FDA for KEYTRUDA® in Classical Hodgkin Lymphoma (cHL)
Merck known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
News
Baxter to Presents broad essential renal and hospital products at the 2016 Bank of America Healthcare Conference
Baxter International Inc will present at the 2016 Bank of America Healthcare Conference on Tuesday, May 10, 2016 in Las Vegas, Nevada. Joe Almeida,...
Clinical Trials
Merck Announces Results From Phase 3 Studies of ZEPATIER™ in Chronic Hepatitis C Patient Populations at The International Liver Congress™
Merck, known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating...
News
Roche receives FDA grants for Venclexta
Roche announced that the U.S. FDA granted accelerated approval to Venclexta™ (venetoclax) for the treatment of people with chronic lymphocytic leukemia (CLL) with 17p...
Research Insight
IMS Health Study: U.S. Drug Spending Growth Reaches 8.5 Percent in 2015
Total spending on medicines in the U.S. reached $310 billion in 2015 on an estimated net price basis, up 8.5 percent from the previous...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read